Patients Ask: Are Poor Sleep and Neurodegenerative Diseases Linked?

February 15, 2022Neelem Sheikh

Worldwide, as many as 38.5 million individuals are living with Alzheimer’s disease, 10 million are living with Parkinson’s disease, and 2.2 million are living with multiple sclerosis. Because neurodegenerative diseases are primarily present in mid-to-late life, the incidence rate is expected to rise rapidly as the population ages. 

While some neurodegenerative diseases originate from non-modifiable factors such as genetics, many neurodegenerative diseases are multifactorial, meaning they develop from a combination of several factors, including modifiable factors such as environment and lifestyle. Poor lifestyle habits, such as an unhealthy diet, insufficient exercise, and alcohol and tobacco use, as well as vascular conditions like high blood pressure and high cholesterol, are among the growing number of modifiable risk factors for neurodegenerative diseases.

Over the past several years, increasing amounts of research have indicated a strong connection between sleep and neurodegenerative diseases—poor sleep resulting from several sleep disorders has been identified as a modifiable risk factor. 

Below, we take a closer look into the connection between sleep and neurodegenerative diseases and the need for early brain health monitoring for those affected by sleep disorders.

Sleep and Neurodegenerative Diseases

It is widely known that sleep-wake disruption is frequently observed in neurodegenerative disease patients and is often one of the earliest reported symptoms. Additionally, sleep-wake abnormalities are frequently accompanied by neurodegenerative or neurotransmitter changes. In other words, while poor sleep is often a symptom of neurodegenerative disease, increasing evidence suggests that poor sleep itself may contribute to the development and progression of neurodegenerative diseases.

Examples of sleep-wake disorders that can cause poor sleep and consequently may contribute to an increased risk of developing neurodegenerative diseases and an increased rate of neurodegeneration include the following:

  • Insomnia
  • Hypersomnolence disorder
  • Narcolepsy
  • Breathing-related sleep disorders
  • Circadian rhythm sleep-wake disorders
  • Rapid eye movement (REM) sleep behavior disorder
  • Non-REM sleep arousal disorders
  • Nightmare disorder
  • Restless leg syndrome
  • Substance/medication-induced sleep disorder

To summarize current research surrounding the connection between sleep and neurodegenerative diseases, here is what we know:

  • Poor sleep is associated with an increased risk for neurodegenerative disease. 
  • Poor sleep is associated with memory lapses and decreased cognitive function. 
  • Sleep deprivation may increase beta-amyloid build-up.
  • Sufficient sleep is linked to increased brain clearance of malignant species.
  • Sufficient sleep is linked to increased performance of cognitive tasks and better memory.

Sleep and neurodegenerative diseases are highly intertwined—their relationship is bidirectional and highly complex. While more research is required to better understand this relationship, the sleep-wake cycle may be an ideal target for potential interventions to slow the progression of neurodegenerative diseases and possibly even prevent their development.

Monitoring Brain Health to Improve Patient Outcomes

The immense amount of research surrounding modifiable risk factors for neurodegenerative disease has emphasized the need for monitoring the brain health of individuals with risk factors, including sleeping disorders. The brain health of all individuals who have known risk factors, whether modifiable or nonmodifiable, should be assessed and monitored—early and longitudinally—to detect neurodegenerative diseases as early as possible. Early detection of many progressive diseases, including neurodegenerative diseases, is crucial, as it can enable early intervention and, consequently, better health outcomes. 

As research continues to identify new novel targets, the neurodegenerative disease drug development pipeline continues to grow, showing immense promise for a future where such diseases are both preventable and treatable. In the meantime, early and frequent monitoring of brain health, early diagnosis, and early intervention remain the most effective path towards fighting the increasing number of neurodegenerative disease cases.

Altoida: Reliable, Affordable, and Accessible Brain Health Monitoring

At Altoida, we are building the world’s first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.

By completing a 10-minute series of augmented reality and motor activities designed to simulate complex ADLs on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.

This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. After our recent Breakthrough Device designation by the FDA, Altoida’s device will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease.

To learn more about the connection between sleep and neurodegenerative diseases or about Altoida’s Precision Neurology platform, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.


Our Disclaimer

@ Altoida 2022